As The Regulatory Environment For Biotech Changes, These 6 Pharma Stocks Have Been Downgraded

With new leadership at the federal agencies that oversee the drug industry, a top Wall Street analyst is warning that the biotech industry and biotech investors “will need to adjust to a different regulatory environment to the one they have enjoyed for the last 5 years” – and has downgraded six pharma stocks due, in part, to the prospect of greater roadblocks for new drug approvals and M&A activity in the drug industry. For more, CLICK HERE.